WANT A PROFILE LIKE THIS?
Gerald H. Lushington
Summary
In a 16-year career, Dr. Gerald Lushington has collaborated on diverse research in drug discovery, molecular biology, chemical synthesis, data mining, and other fields. He has directly supported 29 funded projects in roles ranging from principal investigator, core lead to consultant. Various federal agencies such as the NIH and DOD have supported Lushington's work. Dr. Lushington's research has produced more than 180 peer-reviewed papers, and a Hindex of 38. Serving on multiple external advisory boards, He is Editor for informatics in the journal Combinatorial Chemistry & High Throughput Screening, bioinformatics editor for WebMedCentral, and sits on editorial boards of The Open Enzyme Inhibition Journal, Current Bioactive Compounds, and the Journal of Clinical Bioinformatics. He has reviewed proposals for the U.S. Civilian Research and Development Foundation, the U.S. Defense Threat Reduction Agency, and the Czech Science Foundation. For more than a decade, Gerry Lushington served as a Lab Director at the University of Kansas, in Lawrence, where he managed the technologies in support of scientists, and secured and administered consulting projects with multiple corporations, including Cydex Pharmaceuticals, Inc., Sidley Austin, LLP, and Vanda Pharmaceuticals, Inc. Lushington trained clients on the facility's equipment, configured computational systems, and wrote scientific protocols and analyses. His work there produced a high-performance computational lab comprising 40 cluster processors, six data servers, and 10 work stations supporting a diverse range of modeling and analysis applications. Since mid-2012, Dr. Gerry Lushington has led an independent consultancy, Lushington in Silico, conducting simulation, data analysis, graphics and technical writing services. One of the firm's nine current clients is actively pursuing the commercialization of technology coinvented and patented by Lushington. Since June 2020, Lushington’s primary effort has focused on co-founding a new pharmaceutical startup, Qnapsyn Inc., with a broad pipeline of prospective new therapeutics aimed at metabolic, autoimmune and neurological targets.
